{"id":"sbg","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"SBG works by antagonizing bone morphogenetic proteins, which are key signaling molecules that drive bone formation. By blocking BMP activity, the drug prevents abnormal bone formation in soft tissues. This mechanism is particularly relevant for preventing heterotopic ossification, a condition where bone forms in muscles and other soft tissues where it should not.","oneSentence":"SBG is a bone morphogenetic protein (BMP) antagonist that inhibits heterotopic ossification by blocking BMP signaling pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:33:39.805Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of heterotopic ossification in fibrodysplasia ossificans progressiva (FOP)"}]},"trialDetails":[{"nctId":"NCT06607042","phase":"NA","title":"Study on the Effectiveness of Berlin Dissexuality Therapy as Part of the Model Project in Accordance With §65d SBG V","status":"NOT_YET_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2024-09-16","conditions":"Paedophilia, Hebephilia","enrollment":60},{"nctId":"NCT06473545","phase":"","title":"Retrospective Evaluation of a Novel Biomimetic Synthetic Bone Substitute (Creos® Syntogain)","status":"COMPLETED","sponsor":"International dentistry Research Group","startDate":"2023-04-01","conditions":"Tooth Loss, Partial-edentulism, Tooth Fracture","enrollment":173},{"nctId":"NCT03616444","phase":"PHASE2, PHASE3","title":"A Randomized Clinical Trial of Shenbai Granules in Reducing Recurrence of Colorectal Adenoma","status":"COMPLETED","sponsor":"Jiangsu Famous Medical Technology Co., Ltd.","startDate":"2018-12-03","conditions":"Gastroenterology","enrollment":400},{"nctId":"NCT03501238","phase":"NA","title":"Interaction of Salivary Proteins and Polyphenols","status":"COMPLETED","sponsor":"Purdue University","startDate":"2017-06-08","conditions":"Diet Habit, Diet Modification, Taste, Altered","enrollment":63},{"nctId":"NCT01910597","phase":"PHASE1","title":"Phase I, Dose-Escalation Study of Soluble Beta-Glucan (SBG) in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Prince of Songkla University","startDate":"2013-08-01","conditions":"Advanced Solid Tumors","enrollment":10},{"nctId":"NCT02631512","phase":"PHASE4","title":"Evaluation of Woulgan in Diabetic Foot Ulcer","status":"COMPLETED","sponsor":"Biotec Pharmacon ASA","startDate":"2015-10","conditions":"Diabetic Foot Ulcers","enrollment":62},{"nctId":"NCT03888677","phase":"PHASE3","title":"Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer","status":"COMPLETED","sponsor":"Henrik Lindman","startDate":"2001-02","conditions":"Breast Cancer","enrollment":1535},{"nctId":"NCT02338661","phase":"","title":"Clinical Observation Study With the SBG Stem","status":"COMPLETED","sponsor":"Smith & Nephew Orthopaedics AG","startDate":"2004-01","conditions":"Arthroplasty, Hip Replacement","enrollment":148},{"nctId":"NCT00243607","phase":"NA","title":"Hydrotherapy Against Menopausal Symptoms in Breast Cancer Survivors","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"2006-05","conditions":"Amenorrhea, Hot Flashes","enrollment":45},{"nctId":"NCT00790322","phase":"PHASE3","title":"Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy","status":"COMPLETED","sponsor":"Biotec Pharmacon ASA","startDate":"2008-10","conditions":"Head and Neck Cancer, Oral Mucositis","enrollment":130},{"nctId":"NCT00533364","phase":"PHASE1, PHASE2","title":"Effect of SBG in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Biotec Pharmacon ASA","startDate":"2007-01","conditions":"Breast Cancer","enrollment":11},{"nctId":"NCT00804414","phase":"PHASE3","title":"Efficacy and Safety Study of Soluble Beta-1,3/1,6-glucan (SBG) Versus Placebo in Chronic Diabetic Foot Ulcers","status":"COMPLETED","sponsor":"Biotec Pharmacon ASA","startDate":"2008-10","conditions":"Diabetes, Diabetic Ulcer","enrollment":133},{"nctId":"NCT00632008","phase":"PHASE3","title":"Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers","status":"COMPLETED","sponsor":"Biotec Pharmacon ASA","startDate":"2007-03","conditions":"Chronic Diabetic Foot Ulcers","enrollment":122},{"nctId":"NCT00533728","phase":"PHASE1","title":"Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Biotec Pharmacon ASA","startDate":"2007-09","conditions":"Non-Hodgkin's Lymphoma","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":401,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SBG","genericName":"SBG","companyName":"Biotec Pharmacon ASA","companyId":"biotec-pharmacon-asa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SBG is a bone morphogenetic protein (BMP) antagonist that inhibits heterotopic ossification by blocking BMP signaling pathways. Used for Prevention of heterotopic ossification in fibrodysplasia ossificans progressiva (FOP).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}